Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
We are thrilled to be here in Vancouver for #WD2019! Follow along to learn more about the latest research and importance of #fragilityfracture prevention and managing #osteoporosis. #WD2019 #strengthinherbones. https://t.co/xp0T7jOulX https://t.co/nmGSowP
— UCB News (@ucb_news) 22.05.2019 -
Last year we asked over 4,000 women over 60 if their healthcare professional had ever spoken to them about #osteoporosis and #fragilityfractures. How many do you think said they had? Find more information here https://t.co/yb7yrSDxbp 37% 59% 65% 70% http
— UCB News (@ucb_news) 22.05.2019 -
UCB is committed to sharing information on clinical studies and making the results publicly accessible. To learn more about both ongoing and completed studies, click here: #ClinicalStudies #InspiredByPatients https://t.co/LSMgCJrzis https://t.co/dpNsnrUY
— UCB News (@ucb_news) 22.05.2019
